Analysts’ Top Healthcare Picks: AMRN, BCRX

By Jason Carr

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amarin (NASDAQ: AMRN), BioCryst (NASDAQ: BCRX) and Abbott Labs (NYSE: ABT) with bullish sentiments.

Amarin (NASDAQ: AMRN)

Jefferies analyst Michael Yee reiterated a Buy rating on Amarin (NASDAQ: AMRN) on October 9 and set a price target of $7. The company’s shares closed yesterday at $3.41.

According to TipRanks.com, Yee is a 5-star analyst with an average return of 11.8% and a 65.5% success rate. Yee covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Arbutus Biopharma Corporation, and Proteostasis Therapeutics Inc.

Currently, the analyst consensus on Amarin is Strong Buy and the average price target is $8.25, representing a 141.9% upside.

In a report issued on September 26, Cantor Fitzgerald also assigned a Buy rating to the stock with a $10 price target.
BioCryst (NASDAQ: BCRX)

In a report issued on October 9, Maury Raycroft from Jefferies reiterated a Buy rating on BioCryst (NASDAQ: BCRX), with a price target of $7. The company’s shares closed yesterday at $5.19.

According to TipRanks.com, Raycroft is a 4-star analyst with an average return of 25.4% and a 85.7% success rate. Raycroft covers the Healthcare sector, focusing on stocks such as Karyopharm Therapeutics, Atara Biotherapeutics, and Intellia Therapeutics.

BioCryst has an analyst consensus of Strong Buy, with a price target consensus of $8.

Abbott Labs (NYSE: ABT)

In a report issued on October 10, Raj Denhoy from Jefferies reiterated a Buy rating on Abbott Labs (NYSE: ABT), with a price target of $58. The company’s shares closed yesterday at $54.44, close to its 52-week high of $55.43.

According to TipRanks.com, Denhoy is a 5-star analyst with an average return of 12.8% and a 63.7% success rate. Denhoy covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Varian Medical Systems, and Zimmer Biomet Holdings.

Currently, the analyst consensus on Abbott Labs is Strong Buy and the average price target is $57.29, representing a 5.2% upside.

In a report issued on September 28, Wells Fargo also reiterated a Buy rating on the stock with a $64 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.